These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 34424706)

  • 21. Automated radiosynthesis and preclinical evaluation of Al[
    Huang S; Wu H; Li B; Fu L; Sun P; Wang M; Hu K
    Nucl Med Biol; 2020; 82-83():64-71. PubMed ID: 32088580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of
    Woo SK; Jang SJ; Seo MJ; Park JH; Kim BS; Kim EJ; Lee YJ; Lee TS; An GI; Song IH; Seo Y; Kim KI; Kang JH
    J Nucl Med; 2019 Jan; 60(1):26-33. PubMed ID: 29777007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PET imaging of insulin-like growth factor type 1 receptor expression with a 64Cu-labeled Affibody molecule.
    Su X; Cheng K; Liu Y; Hu X; Meng S; Cheng Z
    Amino Acids; 2015 Jul; 47(7):1409-19. PubMed ID: 25854877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.
    Persson M; Nedergaard MK; Brandt-Larsen M; Skovgaard D; Jørgensen JT; Michaelsen SR; Madsen J; Lassen U; Poulsen HS; Kjaer A
    J Nucl Med; 2016 Feb; 57(2):272-8. PubMed ID: 26429955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-clinical evaluation of immunoPET imaging using agonist CD40 monoclonal antibody in pancreatic tumor-bearing mice.
    Aghevlian S; Wu B; Raie MN; Tumbale SK; Kare AJ; Seo JW; Ferrara KW
    Nucl Med Biol; 2021; 98-99():8-17. PubMed ID: 33962357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.
    Kumar SR; Gallazzi FA; Ferdani R; Anderson CJ; Quinn TP; Deutscher SL
    Cancer Biother Radiopharm; 2010 Dec; 25(6):693-703. PubMed ID: 21204764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship Between Clinicopathological Characteristics and PET/CT Uptake in Esophageal Squamous Cell Carcinoma: [
    Dong Y; Wei Y; Chen G; Huang Y; Song P; Liu S; Zheng J; Cheng M; Yuan S
    Mol Imaging Biol; 2019 Feb; 21(1):175-182. PubMed ID: 29869060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical evaluation of a
    Jadvar H; Chen K; Park R; Yap LP; Vorobyova I; Swenson S; Markland FS
    Amino Acids; 2019 Nov; 51(10-12):1569-1575. PubMed ID: 31621030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of Copper-64-Labeled α
    Ganguly T; Bauer N; Davis RA; Hausner SH; Tang SY; Sutcliffe JL
    Mol Pharm; 2021 Dec; 18(12):4437-4447. PubMed ID: 34783573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting CAIX with [
    Yang X; Zhu H; Yang X; Li N; Huang H; Liu T; Guo X; Xu X; Xia L; Deng C; Tian X; Yang Z
    Mol Pharm; 2019 Apr; 16(4):1532-1540. PubMed ID: 30803240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design of a New
    Hassanzadeh L; Erfani M; Jokar S; Shariatpanahi M
    Curr Radiopharm; 2024; 17(1):77-90. PubMed ID: 37921191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrin α
    Li H; Peng W; Zhen Z; Zhang W; Liao S; Wu X; Wang L; Xuan A; Gao Y; Xu J
    Nucl Med Biol; 2023; 124-125():108364. PubMed ID: 37591041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of [
    Wang M; Zhang H; Wang H; Feng H; Deng H; Wu Z; Lu H; Li Z
    Mol Pharm; 2018 Aug; 15(8):3093-3100. PubMed ID: 29889537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second generation Al
    Spahn MA; Luyten K; Van Loy T; Sathekge M; Deroose CM; Koole M; Schols D; Vanduffel W; De Vos K; Annaert P; Bormans G; Cleeren F
    Nucl Med Biol; 2024; 132-133():108906. PubMed ID: 38518400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [
    Amor-Coarasa A; Kelly JM; Singh PK; Ponnala S; Nikolopoulou A; Williams C; Vedvyas Y; Jin MM; Warren JD; Babich JW
    Molecules; 2019 Apr; 24(8):. PubMed ID: 31022852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
    Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
    Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Homodimeric peptide radiotracer [
    Chen X; Zhang Z; Wang L; Zhang J; Zhao T; Cai J; Dang Y; Guo R; Liu R; Zhou Y; Wei R; Lou X; Xia F; Ma D; Li F; Dai J; Li F; Xi L
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2338-2352. PubMed ID: 38411667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.
    Boyle AJ; Cao PJ; Hedley DW; Sidhu SS; Winnik MA; Reilly RM
    Nucl Med Biol; 2015 Feb; 42(2):71-7. PubMed ID: 25456837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for
    Umbricht CA; Benešová M; Hasler R; Schibli R; van der Meulen NP; Müller C
    Mol Pharm; 2018 Dec; 15(12):5556-5564. PubMed ID: 30376344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. C-terminal-modified LY2510924: a versatile scaffold for targeting C-X-C chemokine receptor type 4.
    Suzuki K; Ui T; Nagano A; Hino A; Arano Y
    Sci Rep; 2019 Oct; 9(1):15284. PubMed ID: 31653903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.